Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with hidradenitis suppurativa — a chronic inflammatory condition that causes painful nodules and abscesses to form under the skin.
It’s the Los Angeles biotech’s first big clinical readout since…
Click here to view original post
